Saturday 17 October 2026
Export EXEL’s income statement to Excel — free account
Exelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024. In the quarter to June 2026, revenue grew 10.6%, EPS grew 25.0% and free cash flow grew 557.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.
62.11
0.72
−1.15%
Follow EXEL
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
6 | 7 | 7 | 4 | 4 | 6 | 5 | 7 | 9 | 7 |
P/E ratio |
0.00 | 59.25 | 8.55 | 16.62 | 54.24 | 24.87 | 28.60 | 36.63 | 18.50 | 15.17 |
Altman Z-Score |
0.33 | 12.76 | 27.49 | 17.32 | 15.41 | 10.00 | 6.54 | 7.86 | 10.04 | 12.68 |
P/S ratio |
19.28 | 20.37 | 6.86 | 5.51 | 6.27 | 4.01 | 3.25 | 4.16 | 4.45 | 5.13 |
P/FCF ratio |
17.67 | 63.74 | 15.31 | 10.37 | 34.63 | 17.10 | 23.38 | 44.69 | 15.24 | 14.10 |
Altman Z″-Score (non-manufacturers) |
(8.78) | (2.89) | 13.73 | 12.24 | 11.11 | 9.94 | 7.65 | 5.76 | 6.99 | 7.69 |
P/Operating CF |
43.36 | 172.79 | 56.02 | 33.74 | 185.83 | 59.68 | 71.12 | 720.21 | 40.20 | 35.69 |
Beneish M-Score |
(0.42) | 0.82 | (0.32) | (3.12) | (2.62) | (2.33) | (2.64) | (2.62) | (2.67) | (2.61) |
P/B ratio |
41.32 | 32.35 | 4.55 | 3.16 | 3.29 | 2.60 | 2.11 | 3.36 | 4.30 | 5.51 |
Price to Tangible BV |
143.96 | 41.66 | 4.79 | 3.29 | 3.41 | 2.68 | 2.16 | 3.46 | 4.43 | 5.67 |
EV/Sales |
17.51 | 19.55 | 6.06 | 4.65 | 5.07 | 3.01 | 2.46 | 3.63 | 3.95 | 4.68 |
EV/EBITDA |
0.00 | 52.94 | 11.67 | 11.92 | 41.98 | 14.36 | 17.79 | 33.78 | 13.53 | 12.06 |
EV/Operating CF |
15.93 | 53.41 | 12.46 | 8.55 | 23.95 | 10.76 | 10.91 | 19.93 | 12.24 | 12.29 |
EV/FCF |
16.05 | 61.16 | 13.53 | 8.76 | 28.01 | 12.81 | 17.65 | 38.99 | 13.52 | 12.87 |
Quick Ratio |
1.71 | 4.08 | 8.12 | 6.80 | 6.68 | 5.18 | 4.70 | 3.13 | 3.41 | 3.32 |
Current Ratio |
1.74 | 4.21 | 8.50 | 7.08 | 7.06 | 5.43 | 4.99 | 3.34 | 3.63 | 3.56 |
Net Debt/EBITDA |
22.46 | (2.23) | (1.56) | (2.26) | (10.12) | (4.89) | (5.88) | (5.06) | (1.75) | (1.18) |
Debt/Assets |
0.00% | 2.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.41 | 0.72 | 0.82 | 0.59 | 0.49 | 0.60 | 0.57 | 0.61 | 0.74 | 0.80 |
Operating CF/Net income |
(3.00) | 1.07 | 0.60 | 1.64 | 1.87 | 1.73 | 1.99 | 1.60 | 1.34 | 1.13 |
Capex/Depreciation |
(0.17) | (17.67) | (6.71) | (1.54) | (3.32) | (4.71) | (6.63) | (6.34) | (2.30) | (1.37) |
Interest Coverage |
(0.85) | 19.12 | 33.76 | 13.20 | 5.50 | 35.83 | 6.11 | — | — | — |
| 272.77% | 82.41% | 87.77% | 21.59% | 6.27% | 11.30% | 7.76% | 8.74% | 23.13% | 35.53% | |
| (15.13%) | 24.66% | 66.43% | 19.41% | 5.56% | 9.72% | 6.41% | 6.91% | 17.70% | 27.02% | |
ROIC |
0.00% | 0.00% | 46.17% | 27.70% | 10.23% | 24.10% | 10.67% | 8.42% | 33.35% | 49.46% |
Return on Tangible Assets |
(34.71%) | 39.00% | 81.91% | 34.99% | 8.55% | 14.43% | 12.97% | 19.74% | 44.06% | 68.85% |
Average Days of Receivables |
77.11 | 65.50 | 69.58 | 44.91 | 59.46 | 71.90 | 48.66 | 47.35 | 44.67 | 45.14 |
Research and Development Expense of Revenue |
50.13% | 24.79% | 21.35% | 34.82% | 55.48% | 48.34% | 55.36% | 57.05% | 41.98% | 35.56% |
Selling, General and Administrative Expense of Revenue |
60.66% | 35.21% | 24.17% | 23.58% | 29.71% | 27.99% | 28.54% | 29.65% | 22.69% | 22.36% |
Intangible Assets out of Total Assets |
0.11 | 0.10 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
Share Based Compensation of Revenue |
11.97% | 5.29% | 4.76% | 5.85% | 10.64% | 8.35% | 6.68% | 5.81% | 4.33% | 4.87% |
Graham Net Nets |
(0.01) | 0.01 | 0.13 | 0.15 | 0.19 | 0.25 | 0.20 | 0.08 | 0.08 | 0.06 |
Graham Number |
0.00 | 3.40 | 14.96 | 11.53 | 7.12 | 10.78 | 9.96 | 10.23 | 17.70 | 22.75 |
Earnings Yield |
(2.38%) | 1.69% | 11.69% | 6.02% | 1.84% | 4.02% | 3.50% | 2.73% | 5.41% | 6.59% |
Free Cash Flow Yield |
5.66% | 1.57% | 6.53% | 9.64% | 2.89% | 5.85% | 4.28% | 2.24% | 6.56% | 7.09% |
Revenue per Share |
0.76 | 1.54 | 2.87 | 3.20 | 3.20 | 4.56 | 5.01 | 5.75 | 7.48 | 8.54 |
Operating CF per Share |
0.84 | 0.56 | 1.40 | 1.74 | 0.68 | 1.27 | 1.13 | 1.05 | 2.41 | 3.26 |
Capex per Share |
(0.01) | (0.07) | (0.11) | (0.04) | (0.10) | (0.20) | (0.43) | (0.51) | (0.23) | (0.15) |
Free Cash Flow per Share |
0.83 | 0.49 | 1.28 | 1.70 | 0.58 | 1.07 | 0.70 | 0.54 | 2.19 | 3.11 |
Cash per Share |
1.68 | 1.32 | 2.33 | 2.82 | 3.91 | 4.66 | 4.07 | 3.13 | 3.83 | 3.90 |
Shareholders Equity per Share |
0.36 | 0.97 | 4.32 | 5.57 | 6.10 | 7.02 | 7.74 | 7.12 | 7.74 | 7.96 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.36 | 0.97 | 4.32 | 5.57 | 6.10 | 7.02 | 7.74 | 7.12 | 7.74 | 7.96 |
Free Cash Flow |
208.80 | 144.63 | 382.73 | 514.12 | 178.64 | 336.58 | 224.16 | 170.36 | 633.79 | 844.34 |
Working Capital |
200.22 | 369.70 | 791.54 | 868.44 | 1,240.74 | 1,497.16 | 1,294.40 | 923.68 | 1,063.81 | 1,037.65 |
Capital Expenditures |
(1.61) | (20.98) | (32.99) | (12.83) | (30.34) | (64.22) | (138.46) | (162.97) | (66.18) | (39.93) |
Net Current Asset Value |
(37.42) | 114.54 | 762.18 | 811.49 | 1,187.18 | 1,429.12 | 1,035.70 | 639.51 | 764.09 | 760.19 |
EV/EBIT |
0.00 | 53.31 | 11.80 | 12.19 | 45.47 | 15.04 | 19.63 | 38.87 | 14.18 | 12.46 |
Capex to Sales |
0.01 | 0.05 | 0.04 | 0.01 | 0.03 | 0.04 | 0.09 | 0.09 | 0.03 | 0.02 |
Price to Operating Income |
0.00 | 55.56 | 13.35 | 14.43 | 56.21 | 20.08 | 26.01 | 44.55 | 15.97 | 13.65 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
4.56 | 0.05 | 0.10 | 0.17 | 0.14 | 0.13 | 0.19 | 0.20 | 0.24 | 0.29 |
Cash ROIC |
41.01% | 21.02% | 19.32% | 20.26% | 5.79% | 9.15% | 5.90% | 5.23% | 18.89% | 26.22% |
Accounts Receivable Turnover |
8.39 | 7.44 | 7.00 | 6.87 | 7.06 | 6.47 | 6.48 | 8.09 | 8.63 | 8.40 |
Accounts Payable Turnover |
0.14 | 0.31 | 2.57 | 2.94 | 2.06 | 2.21 | 2.03 | 2.18 | 2.12 | 2.47 |
Inventory Turnover |
2.20 | 3.01 | 3.19 | 2.91 | 2.14 | 2.18 | 1.91 | 2.87 | 3.84 | 3.80 |
Average Days of Payables |
4,822.38 | 231.97 | 151.01 | 127.72 | 237.81 | 167.46 | 205.90 | 169.89 | 182.90 | 129.19 |
Days of Inventory on Hand |
185.95 | 161.28 | 136.29 | 142.11 | 211.05 | 189.79 | 209.88 | 87.16 | 107.22 | 94.57 |
Average Receivables |
22.81 | 60.82 | 121.98 | 140.92 | 139.97 | 221.76 | 248.72 | 226.10 | 251.42 | 276.18 |
Average Payables |
46.48 | 48.07 | 10.24 | 11.24 | 17.61 | 23.95 | 28.46 | 33.22 | 35.98 | 33.91 |
Average Inventory |
2.98 | 5.00 | 8.25 | 11.36 | 16.93 | 24.23 | 30.40 | 25.31 | 19.86 | 22.04 |
Average Assets |
464.04 | 625.52 | 1,038.79 | 1,653.98 | 2,011.50 | 2,376.79 | 2,843.86 | 3,006.92 | 2,945.02 | 2,896.06 |
Average Common Equity |
(25.74) | 187.14 | 786.21 | 1,486.71 | 1,782.54 | 2,044.86 | 2,349.52 | 2,376.17 | 2,254.06 | 2,202.76 |
Columns are period end dates